OctoPlus wins drug delivery evaluation contract for two compounds

Published: 4-Jun-2009

OctoPlus, a European provider of drug formulation and clinical material manufacturing services, has signed a drug delivery technology evaluation contract for two compounds with an unnamed European biotech company. This is the eighth client for which OctoPlus will work on a controlled release formulation.


OctoPlus, a European provider of drug formulation and clinical material manufacturing services, has signed a drug delivery technology evaluation contract for two compounds with an unnamed European biotech company. This is the eighth client for which OctoPlus will work on a controlled release formulation.

If the evaluations are successful, the contract may progress to a full process development, manufacturing and licensing agreement.

The clinically most advanced product incorporating OctoPlus" technology is Biolex Therapeutics' lead product Locteron, a controlled release formulation of interferon alpha for the treatment of chronic hepatitis C. Locteron is being manufactured for Biolex by OctoPlus and is currently in Phase IIb clinical studies.

You may also like